Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen Inc (PGEN) is a clinical-stage biopharmaceutical leader advancing next-generation gene and cell therapies through its proprietary synthetic biology platforms. This page aggregates official news, press releases, and regulatory developments related to PGEN's innovative research in immuno-oncology, autoimmune disorders, and infectious diseases.
Investors and industry professionals will find timely updates on clinical trial progress, strategic partnerships, and technological breakthroughs leveraging PGEN's UltraCAR-T and AdenoVerse platforms. The curated content supports informed decision-making by providing transparent access to the company's scientific advancements and operational milestones.
Key updates include announcements about therapeutic candidate developments, manufacturing innovations, and collaboration agreements that demonstrate PGEN's position at the forefront of precision medicine. All content is sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to Precigen's latest developments in gene-editing technologies and cellular therapeutics. Regularly updated to reflect PGEN's evolving pipeline and strategic initiatives.
Precigen announced its Q1 2024 financial results and business updates, including pivotal Phase 2 data for PRGN-2012 to be presented at the ASCO Annual Meeting on June 3, 2024. A rolling BLA submission for PRGN-2012 is anticipated in the second half of 2024, with commercial readiness activities underway for a potential 2025 launch. Financially, the company reported $44.8 million in cash, cash equivalents, and short-term investments as of March 31, 2024, with a net loss of $23.7 million or $(0.10) per share. R&D expenses increased by 17%, while SG&A costs decreased by 13%. Key initiatives include PRGN-2009 trials for HPV-associated cancers and PRGN-3006 and PRGN-3005 trials for AML/MDS and ovarian cancer, respectively.
Precigen, Inc. (Nasdaq: PGEN) will report first quarter 2024 financial results on May 14, 2024, with a conference call on June 3, 2024. The company will discuss pivotal Phase 2 study data of PRGN-2012 for recurrent respiratory papillomatosis (RRP) at the 2024 ASCO Annual Meeting. Precigen focuses on gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
